Business Context and Reporting Period
Company: Illumina, Inc. (ILMN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 28, 2025 (52 weeks)
Business Overview: Illumina is a global leader in sequencing- and array-based solutions for genetic and genomic analysis, serving research, clinical, and applied markets. As of December 28, 2025, the company operates as a single reportable segment, "Core Illumina," following the June 2024 spin-off of GRAIL, Inc.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $4.34 billion | $4.37 billion | (1)% |
| Gross Profit | $2.87 billion | $2.86 billion | 0% |
| Gross Margin | 66.1% | 65.4% | +0.7 pts |
| Operating Income | $807 million | ($833 million) | Turnaround to Profit |
| Net Income | $850 million | ($1,223 million) | Turnaround to Profit |
| Diluted EPS | $5.45 | ($7.69) | N/A |
| Operating Cash Flow | $1.08 billion | $837 million | +29% |
| Cash & Equivalents | $1.42 billion | $1.13 billion | +26% |
| Total Debt (Principal) | $2.00 billion | $2.00 billion | 0% |
Note: 2024 results included significant non-cash goodwill and intangible impairments related to GRAIL ($1.89 billion) and a legal settlement gain ($456 million), which are not present in 2025.
Material Changes vs. Prior Period
- Revenue Stability: Core Illumina revenue remained relatively flat ($4.34 billion vs. $4.33 billion in 2024). Consumables revenue increased 2% due to demand for high-throughput products, offset by a 4% decrease in instrument revenue and a 4% decrease in service revenue.
- Profitability Improvement: The company returned to profitability with $850 million in net income, compared to a $1.22 billion loss in 2024. This shift is primarily driven by the absence of the $1.89 billion GRAIL goodwill impairment and the $456 million legal settlement gain recognized in 2024.
- China Impact: Revenue in the Greater China region decreased by $65 million (to $243 million) due to Illumina's inclusion on China's "List of Unreliable Entities" in early 2025, which restricted exports of sequencing instruments.
- Cost Management: Operating expenses decreased significantly on a consolidated basis due to the spin-off of GRAIL. Core Illumina operating expenses were managed through a $100 million cost reduction program implemented in early 2025.
Guidance, Outlook, and Risks
- Strategic Goals: Management aims to achieve revenue growth and improved margin performance by the end of 2027. The company is focusing on operational excellence and capital allocation, including share repurchases.
- Acquisition Activity: On January 30, 2026 (subsequent to year-end), Illumina completed the acquisition of SomaLogic and other assets from Standard BioTools for $350 million in cash, plus potential milestones, to expand its proteomics and multiomics portfolio.
- Share Repurchases: The company repurchased $742 million of stock in 2025. Approximately $643 million of authorization remains available under the current program.
- Key Risks:
- Geopolitical/Regulatory: Continued uncertainty regarding the "List of Unreliable Entities" status in China and potential export restrictions.
- Trade/Tariffs: Tariffs enacted in April 2025 have increased input costs, particularly for imports from Singapore and parts for U.S. manufacturing.
- Funding: Potential reductions in U.S. government funding (NIH) could impact research customer demand.
- Legal: Ongoing shareholder derivative and securities class action lawsuits related to the GRAIL acquisition.
Investor Verification Checklist
- China Exposure: Verify the current status of export restrictions and the long-term impact of the "List of Unreliable Entities" designation on the $243 million Greater China revenue stream.
- Tariff Mitigation: Assess the effectiveness of supply chain optimization and pricing actions in mitigating the cost impact of tariffs enacted in April 2025.
- GRAIL Contingent Value Rights (CVRs): Review the $54 million liability for CVRs and the assumptions used to value future payments based on GRAIL's revenue performance.
- Legal Proceedings: Monitor the status of consolidated shareholder derivative lawsuits and securities class actions regarding the GRAIL acquisition.
- SomaLogic Integration: Evaluate the strategic fit and financial impact of the SomaLogic acquisition completed in January 2026.